General Information

NovoCure, based in St. Helier, Jersey, on one of the English Channel Islands, is a commercial-stage oncology company developing a novel proprietary therapy called TTFields to treat solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low intensity, intermediate frequency, alternating electric fields to exert physical forces on key molecules inside cancer cells. TTFields therapy disrupts normal cell division, leading to the death of cancer cells. 

Employees: 258
Founded: 2000
Contact Information
Address Le Masurier House, La Rue Le Masurier, St. Helier, Jersey JE2 4YE
Phone Number +44 (0)15 3475 6700
Web Address
View Prospectus: NovoCure
Financial Information
Market Cap $1819.0mil
Revenues $34.6 mil (last 12 months)
Net Income $-93.9 mil (last 12 months)
IPO Profile
Symbol NVCR
Exchange NASDAQ
Shares (millions): 7.5
Price range $22.00 - $22.00
Est. $ Volume $165.0 mil
Manager / Joint Managers J.P. Morgan/ Deutsche Bank Securities/ Evercore ISI/ Wells Fargo Securities
CO-Managers JMP Securities/ Wedbush PacGrow
Expected To Trade: 10/2/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change